|
|
| |
Welcome
Chembio Diagnostic Systems, Inc. (Chembio) (OTCQB: CEMI) develops, manufactures, licenses and markets point-of-care (POC) diagnostic tests and technology for the detection of infectious diseases. Founded in 1985, Chembio entered the POC testing field in the late 1990's and, in 2002, focused its business to participate in the emerging global need and opportunity for rapid HIV tests. Today the company is a leading employer on Long Island, with approximately 170 employees. Revenues during the 2nd half of 2011 were nearly $12MM, an annualized rate of $24MM. The company has been profitable since 2009 and anticipates continued revenue growth and profitability in 2012.
Chembio's Dual Path Platform (DPP®) POC technology was awarded United States Patent No. 7,189,522 in March 2007. DPP® enables development of POC assays that provide unique features and capabilities such as multiplexing and improved control of challenging sample types, such as oral fluid. An HIV oral fluid test is anticipated to be submitted to and reviewed by the FDA in 2012. Several other tests have also been developed on DPP® and revenues in this product line are expected to grow significantly in 2012. The company is uniquely positioned to participate in the emerging U.S. market with this and other rapid HIV tests that are already FDA approved for use in professional (i.e. public health and emergency room) settings.
|
The Dual Path Platform (DPP®) Technology
Chembio’s Patented Point-of-Care Testing Platform |
Dual Path Platform
(DPP®)
The Dual Path Platform (DPP®) Technology (US Patent# 7,189,522) was developed as a platform for next generation, rapid diagnostic testing. Chembio believes that this technology allows the freedom to operate in the POC sector and offers a novel, low-cost, rapid technology as an attractive alternative to established point of care formats including lateral flow. Advantages of DPP include increased analytical and clinical sensitivity, multiplexing capabilities and quantifiable results. The technology is available for application in diverse global diagnostic markets for human and veterinary assays, food safety, bioterrorism, environmental testing, etc. |
|
|
|
DPP Features:
- Increased analytical and clinical sensitivity
- Outside the standard lateral flow IP
- Less labor intensive than EIA, PCR or WB
- Potential ideal confirmatory test
- Adaptable to multiple sample types: blood serum, oral fluid, sputum urine, feces, etc.
- Multiplex capability through elimination of
aggregation issues (ie HIV/TB, HIV 1/ 2, etc.)
- Ideally suited for POC testing
- Requires minimal sample volume
- Long shelf life (up to 24 months)
- Total test time < 20 minutes
|
|
Diverse Potential Applications include:
|
|
|
|
|
 |
|
|
 |
|
| |
|
| Date: |
Title: |
| |
|
| 05/08/2012 |
Chembio to Host Conference Call to Discuss 1st Quarter 2012 Financial Results |
| |
|
| 06/16 - 06/19/2012 |
American Society for Microbiology
ASM San Francisco, CA |
| |
|
| 06/18 - 06/21/2012 |
Bio International Conference
Boston Convention & Exhibition
Center, Boston, MA |
| |
|
| 06/27 - 06/29/2012 |
BASHH 2012 Spring Meeting
Jointly held with the ASTDA
Brighton Dome, UK |
| |
|
| 07/15 - 07/19/2012 |
American Association for Clinical
Chemistry AACC Annual Meeting
Los Angeles, CA Booth 2351 |
| |
|
| 11/14 - 11/17/2012 |
MEDICA- Dusseldorf Trade Centre,
Messeplatz, Dusseldorf, Germany |
| |
|
| 12/11 - 12/14/2012 |
APHL- Association of Public Health
Laboratories HIV Testing Conference
Altanta, GA |
| |
|
| 01/28 - 01/31/2013 |
Arab Health Exhibition & Conference
Dubai International Convention &
Exhibition Centre, Dubai |
| |
|
| |
 |
| |
|
|
|
|
|
|
|
|
|
